News
Introducing Proxemis
Related Content
EMIS and the University of Oxford have announced a new joint venture, Proxemis, an end-to-end clinical trial solution specialising in primary care.
Proxemis – which stands for ‘primary care’, ‘Oxford’ and ‘EMIS’ is a new joint venture combining the world-renowned expertise of the University of Oxford's Department of Primary Care, with the software, clinical reach and data management capabilities of Optum (formerly EMIS). Proxemis is reimagining research to support healthier lives with our unique tailored experience for clinical trial delivery.
By leveraging market-leading point-of-care systems used and trusted in over 10,000 healthcare organisations across the UK, Proxemis will integrate research delivery into day-to-day care to help address long-term conditions and health inequalities.
By focusing particularly on clinical trials that are suited to be conducted in primary care settings, Proxemis aims to make it easier for both patients and clinicians to participate in research and help find better treatments for long-term conditions.
Proxemis will be able to help design a study specifically to target relevant patient cohorts, particularly around a chronic condition, recruit patients for the study and enable a successful clinical trial.
The joint venture was announced at the Outsourcing Clinical Trials conference in Barcelona (4 May 2023), where we showcased EMIS’s Recruit solution, which is helping the NHS to embed clinical research at the heart of patient care.
The business will have a board consisting of three directors from Optum: John McCormack, Alex Eavis and Lucy Mackillop and three from the University of Oxford: Professor Richard Hobbs, Bernard Taylor and Linda Naughton.
See below to find out more about Proxemis.